Tests chest radiotherapy after chemo-immunotherapy for small-cell lung cancer
Tests chest radiotherapy in adults with extensive small-cell lung cancer after standard treatment.
Key facts
- Who runs it
- Ruijin Hospital
- Where
- Shanghai, ChinaSee the site
- Trial code
- Registry title
- Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
- Status
- Recruiting
- People taking part
- 104 people, planned
- Started
- 30 Jan 2021
- Expected to end
- 30 Sept 2027
- Type of study
- Interventional
- Treatments tested
- thoracic radiotherapy
- Record updated
- 12 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with extensive-stage small-cell lung cancer who had chemo-immunotherapy and PD-1/PD-L1 maintenance, and will test radiotherapy to the chest.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Small-cell lung cancer confirmed by tissue or cell tests, stage III-IV, with at least one measurable chest tumour that can be irradiated with 45 Gy/15 fractions.
- Earlier treatment
- Cannot have had earlier chemotherapy, immunotherapy or radiotherapy for small-cell lung cancer.
Main reasons for not taking part
- Major surgery in the last 28 days
- Past organ transplant from a donor, autoimmune disease, immunodeficiency, hepatitis or HIV
- Another active cancer
- Cancer spread to the membranes around the brain and spinal cord (leptomeningeal carcinomatosis)
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Age between18 years and 80 years at time of study entry
- ECOG performance status of 0 or 1
- Body weight >30 kg
- Adequate bone marrow, liver and kidney function
- Life expectancy of at least 3 months
- At least one measurable (RECIST 1.1), thoracic lesion that can be irradiated with 45 Gy/15 fractions
- Histologic or cytologic confirmation of small cell lung cancer
- Stage III-IV disease (TNM v8)
- Adequate pulmonary function with FEV1 >1 L or >30 % of predicted value and DLCO >30 % of predicted value
- Patients with brain metastases are eligible provided they are asymptomatic or treated and stable on steroids and/or anticonvulsants prior to the start of treatment -
Who cannot take part
- Previous chemo-, immuno- or radiotherapy for SCLC
- Major surgical procedure last 28 days
- Immunosuppressive medication
- History of allogenic organ transplantation, autoimmune disease, immunodeficiency, hepatitis or HIV
- Uncontrolled intercurrent illness
- Other active malignancy
- Leptomeningeal carcinomatosis
- Pregnant or breastfeeding women
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in China
- Ruijin Hospital, Shanghai jiaotong univestigy school of medicineShanghai, ChinaContact: Yifeng WangTaking people
About the trial
What the trial wants to find out
This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of thoracic radiotherapy for extensive-stage small-cell lung cancer treated with PD-1/PD-L1 plus etoposide platinum followed by PD-1/PD-L1 maintenance therapy
The group in the trial
- experimental groupTreatment being tested
chemo-immunotherapy followed by thoracic radiotherapy and PD-1/PD-L1 maintenance therapy
Treatment: thoracic radiotherapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Consolidative Thoracic Radiotherapy for Extensive-stage Small-cell Lung Cancer Treated With Chemo-immunotherapy Followed by PD-1/PD-L1 Maintenance Therapy：an Open Label, Single Arm Prospective Trial
- Plain-language title
- Tests chest radiotherapy after chemo-immunotherapy for small-cell lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05552846, who can take part
- Record updated
- 12 August 2026